Vaxart (VXRT) said late Monday an independent data safety monitoring board has recommended that a phase 2b trial of its oral Covid-19 vaccine candidate continue without any modifications.
The company said the US Food and Drug Administration is reviewing the safety data from the study.
Upon favorable review, the company will enroll about 10,000 participants for the next phase of the trial, which seeks to compare the Vaxart pill with mRNA Covid-19 jabs, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.